<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Developing and Refining New Candidate Criteria for SLE Classification: An International Collaboration</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2018-06-12">2018 June 12.</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>MD, MPH</roleName><forename type="first">Sara</forename><forename type="middle">K</forename><surname>Tedeschi</surname></persName>
							<email>stedeschi1@bwh.harvard.edu</email>
							<affiliation key="aff0">
								<orgName type="department">Brigham and Women&apos;s Hospital</orgName>
								<orgName type="institution">Harvard Medical School</orgName>
								<address>
									<settlement>Boston</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sindhu</forename><forename type="middle">R</forename><surname>Johnson</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Toronto Western Hospital</orgName>
								<orgName type="institution">University of Toronto</orgName>
								<address>
									<region>Ontario</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dimitrios</forename><surname>Boumpas</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">University of Crete</orgName>
								<address>
									<settlement>Heraklion</settlement>
									<country key="GR">Greece</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Daikh</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution">University of California San Francisco</orgName>
								<address>
									<settlement>San Francisco</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">VA Medical Center</orgName>
								<address>
									<settlement>San Francisco</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thomas</forename><surname>Dörner</surname></persName>
							<affiliation key="aff5">
								<orgName type="institution">Charite University Hospitals</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Jayne</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Diane</forename><surname>Kamen</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution">Medical University of South Carolina</orgName>
								<address>
									<settlement>Charleston</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kirsten</forename><surname>Lerstrøm</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution">LUPUS EUROPE</orgName>
								<address>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marta</forename><surname>Mosca</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution">University of Pisa</orgName>
								<address>
									<settlement>Pisa</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rosalind</forename><surname>Ramsey-Goldman</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">Northwestern University</orgName>
								<address>
									<settlement>Chicago</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Corine</forename><surname>Sinnette</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Brigham and Women&apos;s Hospital</orgName>
								<orgName type="institution">Harvard Medical School</orgName>
								<address>
									<settlement>Boston</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Wofsy</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution">University of California San Francisco</orgName>
								<address>
									<settlement>San Francisco</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Josef</forename><forename type="middle">S</forename><surname>Smolen</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">Medical University of Vienna</orgName>
								<address>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Raymond</forename><forename type="middle">P</forename><surname>Naden</surname></persName>
							<affiliation key="aff12">
								<orgName type="institution">McMaster University</orgName>
								<address>
									<settlement>Hamilton</settlement>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Aringer</surname></persName>
							<affiliation key="aff13">
								<orgName type="institution" key="instit1">University Medical Center Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit2">Technical University of Dresden</orgName>
								<address>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Karen</forename><forename type="middle">H</forename><surname>Costenbader</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Brigham and Women&apos;s Hospital</orgName>
								<orgName type="institution">Harvard Medical School</orgName>
								<address>
									<settlement>Boston</settlement>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff14">
								<orgName type="department" key="dep1">Brigham and Women&apos;s Hospital</orgName>
								<orgName type="department" key="dep2">Division of Rheumatology, Immunology and Allergy</orgName>
								<address>
									<addrLine>60 Fenwood Road</addrLine>
									<postCode>02115</postCode>
									<settlement>Boston</settlement>
									<region>MA</region>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Developing and Refining New Candidate Criteria for SLE Classification: An International Collaboration</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2018-06-12">2018 June 12.</date>
						</imprint>
					</monogr>
					<idno type="MD5">67224461A2D08802543127EC1A7BAD96</idno>
					<idno type="DOI">10.1002/acr.23317</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:20+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>systemic lupus erythematosus</term>
					<term>classification criteria</term>
					<term>methodology CNS manifestations (seizures, psychosis, chorea, myelitis, optic</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Objectives-We aimed to define candidate criteria within multi-phase development of SLE classification criteria, jointly supported by EULAR and ACR.</s><s>Prior steps included item generation and reduction by Delphi exercise, further narrowed to 21 items in a Nominal Group Technique exercise.</s><s>Our objectives were to apply an evidence-based approach to the 21 candidate criteria, and to develop hierarchical organization of criteria within domains.</s></p><p><s>Methods-A literature review identified the sensitivity and specificity of the 21 candidate criteria.</s><s>Data on the performance of ANA as an entry criteria and operating characteristics of the candidate criteria in early SLE patients were evaluated.</s><s>Candidate criteria were hierarchically</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>The 1982 American College of Rheumatology (ACR) classification criteria for SLE and their 1997 revision have shaped our understanding of SLE and been used widely in lupus research for decades.</s><s>However, novel information on the disease has emerged, such as the recognition of subacute cutaneous lupus erythematosus (SCLE) as an SLE manifestation, and the Systemic Lupus International Collaborating Clinics (SLICC) group showed that their sensitivity is suboptimal.</s><s>On the other hand, while introducing important new concepts, the SLICC 2012 criteria have only partially succeeded in better performance, in that they had increased sensitivity at the price of reduced specificity.</s><s>It appears likely that this decrease in specificity is due to maintaining the overall structure of the ACR criteria, which assigns equal weights to each criterion.</s><s>While SLICC criteria require the presence of at least one clinical and one immunologic criterion, both the ACR and SLICC criteria classify SLE based a simple count of the number of criteria present.</s><s>Due to the heterogeneity of SLEranging from mild to severe symptoms with a variety of organ manifestations-the overall performance of SLE classification criteria could be further increased by developing a weighted scoring system.</s><s>This is particularly true for early phases of the disease, where both ACR and SLICC criteria perform worse than in established SLE.</s></p><p><s>Since 2014, a Steering Committee equally appointed by the European League Against Rheumatism (EULAR) and the ACR (n=12) has been working on developing new classification criteria for systemic lupus erythematosus (SLE) for clinical research purposes.</s><s>This effort involves hundreds of SLE experts worldwide.</s><s>The overarching goal is to develop a system to identify potential participants for clinical research studies, which requires some degree of homogeneity across subjects, while simultaneously dealing with the extreme heterogeneity of SLE.</s><s>As with previously established classification criteria, the goal is to arrive at a system with the maximum combination of sensitivity and specificity for SLE, retaining face validity. <ref type="bibr" target="#b0">1</ref></s><s>2]<ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b7">[7]</ref><ref type="bibr" target="#b9">[8]</ref><ref type="bibr" target="#b11">[9]</ref> The item generation and reduction phases of this approach were completed by a Nominal Group Technique exercise <ref type="bibr" target="#b9">8</ref> that produced 21 candidate criteria-two of which were proposed as candidate entry criteria-summarized in Table <ref type="table" target="#tab_2">1</ref>.</s></p><p><s>Three important issues were raised during the Nominal Group Technique exercise.</s><s>First, it was important to understand the validity of each of the candidate criteria, particularly their sensitivity and specificity. <ref type="bibr" target="#b4">5</ref></s><s>Second, a lack of precise definitions for the candidate criteria would result in inconsistent interpretation and application of the criteria, affecting the validity and reliability of the final classification system.</s><s>Finally, clustering the criteria into 'buckets' or domains was recommended as a next step.</s></p><p><s>We report the process of refining the criteria for SLE classification.</s><s>The goals were to apply an evidence-based approach to the 21 candidate criteria, and to develop hierarchical organization of criteria within domains.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Literature review for test performance characteristics of candidate criteria</head><p><s>Two investigators (KHC, SKT) conducted a literature review on sensitivity and specificity of the candidate SLE criteria using PubMed.</s><s>This step was foundational for subsequent steps, as sensitivity and specificity are among the most important aspects to consider when developing classification criteria. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b12">10</ref> </s><s>everal manuscripts have reported the prevalence of specific manifestations in SLE cohorts, but for the purposes of classification criteria development, it was important to evaluate both sensitivity and specificity in the same dataset.</s><s>In the evaluative process, the following principles were considered:</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>•</head><p><s>Sensitivity for SLE represents prevalence of a criterion in a given SLE population.</s><s>Thus, the SLE population being studied affects the sensitivity.</s></p><p><s>• Specificity for SLE is contingent upon the comparator (non-SLE) population.</s><s>For example, specificity of oral ulcers for SLE is the ratio of comparator patients without oral ulcers to the entire comparator population.</s><s>Using a comparator population of Crohn's disease patients, who may develop oral ulcers as part of their disease, will produce different specificity than using a comparator population of rheumatoid arthritis patients among whom oral ulcers are uncommon.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Identification of domains</head><p><s>After reviewing the literature, the candidate criteria were clustered into independent domains.</s><s>This was an iterative process, with input from the Steering Committee.</s><s>Based on the development of published criteria sets <ref type="bibr" target="#b13">[11]</ref><ref type="bibr" target="#b14">[12]</ref><ref type="bibr" target="#b15">[13]</ref><ref type="bibr" target="#b16">[14]</ref> and consultation with an expert in additive point systems for disease classification (RPN), the following principles for domain development were proposed:</s></p><p><s>• Classification criteria should be organized into 8-10 domains, each containing 2-3 criteria;</s></p><p><s>• Domains should be independent from one another, and therefore additive;</s></p><p><s>• Within a domain, criteria should be ordered from least to most influential (i.e.</s><s>least specific to most specific) regarding their importance when considering the likelihood of a patient being classified as having the disease;</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>•</head><p><s>Only the one most influential criterion in each domain will be scored;</s></p><p><s>• Scores from all domains will be summed to produce a final SLE classification score.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>In-person meeting at the EULAR 2016 Congress</head><p><s>During a one-day meeting, the literature review and a draft hierarchical organization of criteria within domains were presented to the Steering Committee and two patient representatives from Lupus Europe for feedback and comment.</s><s>Challenges with drawing generalizable conclusions from the literature review, such as the use of different comparator populations for sensitivity and specificity calculations, and definitions used in past criteria were discussed.</s><s>Definitions and the order within domains were further refined.</s><s>The reliability (i.e.</s><s>reproducibility between clinicians and within individual clinicians) of the candidate clinical criteria was discussed.</s><s>The precision and availability of candidate immunologic assays were discussed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessment of face and content validity of domains and criteria</head><p><s>Following the in-person meeting, the domains and criteria were further refined through an iterative process.</s><s>Changes to the number and content of domains, and criteria within domains, were made in response to feedback given during the discussions.</s><s>The guiding principles were that criteria should be sensitive for SLE (i.e.</s><s>prevalent in SLE cohorts), criteria should be arranged in order of increasing specificity for SLE, and domains must be independent.</s><s>Additionally, candidate criteria were assessed for creditability (face validity) and comprehensiveness (content validity) to reflect all aspects of SLE. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b4">5</ref> </s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Literature review and performance characteristics of candidate criteria</head><p><s>The sources of sensitivity and specificity data were: American Rheumatism Association (ARA) 1971 preliminary SLE classification criteria, <ref type="bibr" target="#b17">15</ref> ACR 1982 revised criteria for the classification of SLE and the 1997 update of these criteria, <ref type="bibr" target="#b18">16,</ref><ref type="bibr" target="#b19">17</ref> Systemic Lupus International Collaborating Clinics (SLICC) 2012 classification criteria for SLE, <ref type="bibr" target="#b20">18</ref> data from a recent, early SLE (diagnosed in the preceding 12 months) cohort study, <ref type="bibr" target="#b21">19</ref> and a recent, large study of test characteristics of low complements in new-onset SLE. <ref type="bibr" target="#b23">20</ref></s><s>These study populations are summarized in Table <ref type="table" target="#tab_4">2</ref>. Sensitivity and specificity data for the candidate criteria are summarized in Table <ref type="table" target="#tab_5">3</ref>.</s><s>When present, published definitions were reviewed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Definitions for candidate criteria</head><p><s>While the complete list of candidate criteria is shown in Table <ref type="table" target="#tab_2">1</ref>, and previous classification criteria definitions are detailed in Table <ref type="table" target="#tab_5">3</ref>, discussions on several items were critical and are therefore presented here in more detail.</s></p><p><s>Fever-Fever was not included in previous classification criteria.</s><s>In the early SLE cohort, fever was present in 34% of SLE patients vs. 14% of patients with conditions only mimicking SLE (mimickers). <ref type="bibr" target="#b21">19</ref></s><s>Fever of unknown origin is defined as &gt;38.3 Celsius for &gt;3 weeks with no source identified after one week of investigation. <ref type="bibr" target="#b24">21</ref></s><s>This definition had not been studied in SLE.</s></p><p><s>Alopecia with associated scalp inflammation-The ACR 1982 classification criteria omitted alopecia as "it did not perform well in distinguishing SLE from scleroderma and dermato/polymyositis [data not shown]." <ref type="bibr" target="#b18">16</ref></s><s>The ARA 1971 SLE classification criteria and SLICC 2012 SLE classification criteria both defined alopecia as non-scarring.</s></p><p><s>Acute cutaneous lupus-The ACR 1982 criteria included two independent acute cutaneous lupus criteria: malar rash and photosensitivity, while the SLICC 2012 definition included malar rash, bullous lupus, toxic epidermal necrolysis variant of SLE, maculopapular lupus rash, and photosensitive lupus rash in the absence of dermatomyositis.</s></p><p><s>Subacute cutaneous lupus was observed in 4.6% of a large European cohort, <ref type="bibr" target="#b25">22</ref> and a 1981 dermatology report estimated 10-15% prevalence in SLE. <ref type="bibr" target="#b26">23</ref></s><s>We did not find specificity data for subacute cutaneous lupus.</s></p><p><s>We reviewed skin biopsy histopathology definitions developed through an international Delphi consensus process of relevant stakeholders at the 2013 International Meeting on Cutaneous Lupus Erythematosus. <ref type="bibr" target="#b27">24</ref></s><s>Interface vacuolar dermatitis was common to acute cutaneous, subacute cutaneous, and discoid lupus.</s><s>Immunofluorescence findings were not specifically mentioned.</s></p><p><s>Chronic cutaneous lupus-The Gilliam 1981 classification of chronic cutaneous lupus erythematosus included discoid lupus, and excluded lupus profundus/panniculitis, chilblain lupus, and lupus tumidus. <ref type="bibr" target="#b26">23</ref></s><s>The ACR 1982 criteria included only discoid lupus, whereas the expanded SLICC criteria included: classic discoid rash (localized above the neck, or generalized), hypertrophic (verrucous) lupus, lupus panniculitis (profundus), mucosal lupus, lupus erythematosus tumidus, chilblains lupus, and discoid lupus/lichen planus overlap.</s><s>Test characteristics of these single entities were not reported.</s></p><p><s>CNS manifestations-The ACR 1982 classification criteria included a neurologic criterion with two possible manifestations: seizures or psychosis, in the absence of other causes.</s><s>SLICC included both central nervous system (CNS) and peripheral nervous system (PNS) manifestations.</s><s>CNS manifestations were: seizures, psychosis, cranial neuropathy, and acute confusional state in the absence of other causes.</s></p><p><s>Among 1,206 early SLE patients with mean disease duration of 5.4 (standard deviation [SD] 4.</s></p><p><s>2) months at enrollment and mean 1.9 (SD 1.2) years of follow-up, 486 (40.3%) had a neuropsychiatric event, most commonly headache and mood disorder. <ref type="bibr" target="#b28">25</ref></s><s>Among these 486 patients, 13-24% of neuropsychiatric events were attributable to SLE depending on the decision rule applied.</s><s>Another study reported that most SLE CNS manifestations occur in patients with lupus anticoagulant, anti-cardiolipin, or anti-dsDNA antibodies. <ref type="bibr" target="#b29">26</ref></s><s>This raised questions about the etiology of CNS events and whether they are predominantly consequences of antiphospholipid syndrome (APS).</s></p><p><s>In the early SLE cohort, seizures were among the presenting manifestations in 2.8%, psychosis in 1%, and stroke in 1%. <ref type="bibr" target="#b21">19</ref></s><s>The definition for each of these diagnoses was not specified.</s><s>Definitions of neurologic criteria from the ACR 1999 Ad Hoc Committee on Neuropyschiatric Lupus were reviewed and are presented in Table <ref type="table" target="#tab_2">1</ref> (Neurologic domain). <ref type="bibr" target="#b30">27</ref></s><s>troke was omitted as it is most commonly a manifestation of long-standing SLE in the context of cerebrovascular risk factors and/or APS.</s><s>The ACR 1999 publication indicated that "acute confusional state" was synonymous with "delirium"; the latter term was adopted due to clinical familiarity.</s></p><p><s>Serositis-In ACR 1982 criteria, serositis included "pleuritis," characterized by a convincing history of pleuritic pain or a pleuritic rub heard by a physician or evidence of pleural effusion, or "pericarditis" documented by EKG or rub or evidence of pericardial effusion. <ref type="bibr" target="#b18">16</ref></s><s>SLICC defined serositis as "typical pleurisy for &gt;1 day or pleural effusions or pleural rub", or "typical pericardial pain (pain with recumbency improved by sitting forward) or pericardial effusion or pericardial rub or pericarditis by electrocardiography [EKG]" in the absence of other causes. <ref type="bibr" target="#b20">18</ref></s><s>We did not find data on sensitivity or specificity of abdominal serositis in SLE.</s></p><p><s>The European Society of Cardiology 2015 Guidelines for diagnosis and management of pericardial diseases defined acute pericarditis as an inflammatory syndrome with ≥2 of the following: (1) pericarditic chest pain ("typically sharp and pleuritic, improved by sitting up and leaning forward"), (2) pericardial friction rub, (3) new widespread ST-elevation or PR depression on EKG, (4) pericardial effusion (new or worsening). <ref type="bibr" target="#b31">28</ref></s><s>This definition has not been evaluated in SLE to our knowledge.</s></p><p><s>Lupus nephritis-The ACR 1982 criteria did not include renal biopsy.</s><s>Biopsy-proven lupus nephritis in the setting of positive ANA or anti-dsDNA antibodies is considered sufficient for classification as SLE using the SLICC classification criteria.</s><s>The SLICC publication did not present sensitivity or specificity data for renal biopsy, however.</s><s>We reviewed lupus nephritis renal histopathology definitions from the International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Classification system. <ref type="bibr" target="#b33">29</ref></s><s>These definitions include characteristic findings by both light microscopy and immunofluorescence.</s></p><p><s>Active urine sediment was defined as "cellular casts -may be red cell, hemoglobin, granular, tubular, or mixed" in the ACR 1982 criteria. <ref type="bibr" target="#b18">16</ref></s><s>SLICC criteria include urinary red blood cell (RBC) casts as the sole indicator of an active urine sediment.</s><s>ACR 2006 criteria for response in SLE clinical trials defined active urine sediment as &gt;5 RBC/high power field (hpf) and &gt;5 WBCs/hpf and/or ≥1 cellular cast. <ref type="bibr" target="#b34">30</ref></s><s>However, urinary RBC ≤5/hpf had low sensitivity and specificity in predicting improved renal function at 12 months in the Euro-Lupus Nephritis cohort. <ref type="bibr" target="#b35">31</ref></s><s>tiphospholipid antibodies-The 1997 update to ACR 1982 criteria included antiphospholipid antibodies as follows: "abnormal" ACL IgG or IgM, or positive lupus anticoagulant, or false-positive serologic test for syphilis for at least six months and confirmed by a second test. <ref type="bibr" target="#b19">17</ref></s><s>SLICC criteria assign points for the presence of ≥1 of the following: positive lupus anticoagulant; false-positive rapid plasma reagin; medium-or hightiter anti-cardiolipin (ACL) IgA, IgG, or IgM (titers not defined); positive anti-β2glycoprotein I (anti-β2GP1) IgA, IgG, or IgM.</s><s>The need for repeat testing was not specified.</s></p><p><s>A 2006 international consensus statement updating the Sapporo Criteria stated that APS requires one of the following: ACL IgG &gt;40 GPL units or IgM &gt;40 MPL units; anti-β2GP1 IgG or IgM &gt;99 th percentile; and/or positive lupus anticoagulant. <ref type="bibr" target="#b36">32</ref></s><s>Per email discussion with an international expert on antiphospholipid antibodies, most clinical laboratories do not report the percentile for anti-β2GP1 IgG or IgM (D. Erkan, personal communication).</s></p><p><s>Complement proteins-ACR 1982 criteria do not include complements because, "we were unable to improve accuracy by using any combination of serum complement determinations, either as a separate criterion or by adding these determinations into one of the other combined variables." <ref type="bibr" target="#b18">16</ref></s><s>SLICC criteria include low C3, low C4, or low CH50.</s><s>In a large study of newly-diagnosed SLE and non-SLE patients, complement assays were performed by immunization rate scattering turbidimetry; low C3 was &lt;0.79 g/L and low C4 was &lt;0.16 g/L. <ref type="bibr" target="#b23">20</ref></s><s>esence of multiple autoantibodies-In the early SLE cohort, anti-Ro antibody was present in 25% of SLE patients vs. 23% of mimickers; anti-La antibody was found in 11% of SLE vs. 9% of mimickers.</s><s>Anti-U1-RNP was detected more frequently in SLE (22%) vs. mimickers (5%). <ref type="bibr" target="#b21">19</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Identification of domains</head><p><s>Clinical and immunologic domains identified before the EULAR 2016 Congress meeting included:</s></p><formula xml:id="formula_0">• Clinical domains • Constitutional • Cutaneous • Arthritis • Serositis • Hematologic • Renal •</formula><p><s>Neurologic was not included as a domain prior to this meeting; however, during phone calls and emails in the months after the meeting, consensus was reached about including a Neurologic domain as defined in Table</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>In-person meeting at the EULAR 2016 Congress</head><p><s>Data from the literature review, the proposed clinical and immunologic domains, and proposed clustering of criteria within domains, were reviewed.</s><s>In applying the criteria, consensus was achieved for: (Table <ref type="table" target="#tab_2">1</ref>)</s></p><p><s>• "For each criterion, do not score if a cause more likely than SLE exists (such as infection, malignancy, medication, rosacea, endocrine disorder, other autoimmune disease)."</s><s>This statement was proposed to avoid redundancy in stating "in the absence of [insert specific causes]" after each criterion.</s><s>This statement may be bolded on the final version of the scoring form to emphasize its great importance in scoring each criterion, and it underscores the clinical judgment and experience of the clinician scoring the patient.</s></p><p><s>• "Occurrence of a criterion on at least one occasion is sufficient."</s><s>This is an important change compared to the ACR 1982 hematologic criteria, and is grounded in more recent data.</s></p><p><s>• "Criteria need not occur simultaneously."</s><s>This statement reflects that SLE can evolve over time, with new manifestations appearing years after diagnosis.</s></p><p><s>• "At least one clinical criterion must be present."</s><s>The group agreed that for the purposes of clinical research, the new classification criteria should not classify an asymptomatic patient as having SLE based on positive serologies only.</s></p><p><s>• "Within each domain, only the highest weighted criterion is counted toward the total score."</s><s>This is based on the fact that symptoms in one category, such as leukopenia and thrombocytopenia, could stem from a non-SLE (e.g.</s><s>bone marrow) disease.</s></p><p><s>It was also decided that the new criteria should avoid classifying patients with positive ANA and only cutaneous manifestations as SLE.</s><s>It was agreed that ANA ≥1:80 by HEp2 immunofluorescence would be an entry criterion (e.g. must be present to be considered for classification as SLE), with the addition of the phrase "history of," as patients with SLE may have a positive ANA that later normalizes. <ref type="bibr" target="#b11">9</ref></s><s>Because of the relatively low sensitivity of low complement levels identified through literature review, it was agreed that this should not be an entry criterion and it was re-assigned as an Immunologic domain.</s></p><p><s>Discussions about candidate criteria are summarized in Supplemental File 1.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>In this phase of SLE classification criteria development, we applied a data-driven, consensus-based approach to categorize candidate criteria into independent domains.</s><s>Through literature review, we synthesized the test performance characteristics of candidate criteria under consideration for classification of SLE.</s><s>We then refined definitions for the candidate criteria, thereby improving the validity and reliability of the final classification system.</s><s>Additionally, we adhered to the recommendation of SLE experts to cluster criteria into domains, creating hierarchical organization of criteria within domains. <ref type="bibr" target="#b9">8</ref></s><s>r literature review revealed knowledge gaps about the sensitivity and specificity of some of the newly proposed criteria, thus expert consensus and patient input was critical for decision making.</s><s>This was evident, for example, in the discussion regarding neurologic manifestations of SLE.</s><s>Individual CNS and PNS manifestations have a low prevalence and consequently poor operating characteristics in SLE.</s><s>In addition, it has been recognized that the attribution of neurologic events to SLE is difficult, and these events can occur up to 20 years before SLE diagnosis. <ref type="bibr" target="#b38">33</ref></s><s>However, both SLE experts and patients felt it was important to retain this domain into the next phase, for further testing.</s></p><p><s>Similarly, the concept of "presence of multiple autoantibodies" was an appealing criterion to many experts.</s><s>However, it was evident that antibodies already part of candidate items by themselves could not be included, and antibodies that were not testable worldwide should not be included.</s><s>This would preclude the feasibility of the final criteria system.</s><s>Anti-Ro, anti-La, and anti-RNP antibodies remained for consideration.</s><s>However, whether the presence of these antibodies increases or decreases the likelihood of SLE is highly dependent on the clinical context.</s><s>For example, a patient with ANA 1:160 by Hep2 immunofluorescence, positive anti-Ro and anti-La antibodies, sicca syndrome, and no other signs or symptoms likely has primary Sjögren's syndrome; in this case, anti-Ro and anti-La antibodies should carry negative weight for likelihood of SLE.</s><s>Another patient with the same autoantibody profile, inflammatory arthritis, and pericarditis would be more properly classified as SLE; in this scenario, anti-Ro and anti-La antibodies should not detract from the likelihood of SLE, but whether they add to it is unclear.</s></p><p><s>With clarity on the definitions of the candidate criteria, their operating characteristics, and the hierarchical organization of criteria within domains, <ref type="bibr" target="#b9">8</ref> we are able to embark on the next phase of criteria development.</s><s>In Phase III, ascertainment of criteria weights, possible further refinement of criteria and identification of a threshold for classification will be achieved using multicriteria decision analysis.</s><s>It is anticipated that this will result in a numeric additive point system that will assign a probability that an individual with a combination of particular signs and symptoms can be classified as SLE.</s><s>This scoring system will undergo validation and comparison against pre-existing classification systems.</s><s>5]<ref type="bibr" target="#b41">[36]</ref><ref type="bibr" target="#b42">[37]</ref> These assays are not yet universally accepted or commercially available, and thus not ready for incorporation in disease classification criteria.</s><s>However, as attempts at the cellular and molecular characterization of SLE are underway, it will be interesting to see whether they will support this clinically-derived set of SLE classification criteria and the underlying concepts-or radically change our ways of thinking about SLE classification.</s><s>• Occurrence of a criterion on at least one occasion is sufficient.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>•</head><p><s>Criteria need not occur simultaneously.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>•</head><p><s>At least one clinical criterion must be present.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>•</head><p><s>Within each domain, only the highest weighted criterion is counted toward the total score.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Domains and Criteria</head><p><s>Fever (definition to be determined) Constitutional domain:</s></p><formula xml:id="formula_1">Fever: &gt;38.</formula></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>Photosensitivity</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 1</head><label>1</label><figDesc><div><p><s>Evolution of candidate SLE classification criteria in a multi-phase development process</s></p></div></figDesc><table><row><cell>Nominal Group Technique (2015)</cell><cell cols="2">Literature Review and Iterative Revisions (through October 2016)</cell></row><row><cell>Entry criteria</cell><cell></cell></row><row><cell>ANA by HEp 2 immunofluorescence</cell><cell cols="2">History of a positive ANA by HEp 2 immunofluorescence ≥1:80</cell></row><row><cell>≥1:80</cell><cell></cell></row><row><cell>Low C3 and/or low C4</cell><cell cols="2">[Not an entry criterion, but included as a domain]</cell></row><row><cell>Criteria</cell><cell></cell></row><row><cell>Candidate additive criteria, listed in no</cell><cell cols="2">Criteria were grouped into domains. Items within domains were listed in order of increasing</cell></row><row><cell>particular order</cell><cell cols="2">importance. The following Opening Statements were agreed upon:</cell></row><row><cell></cell><cell>•</cell><cell>For each criterion, do not score if a cause more likely than SLE exists (such as</cell></row><row><cell></cell><cell></cell><cell>infection, malignancy, medication, rosacea, endocrine disorder, other autoimmune</cell></row><row><cell></cell><cell></cell><cell>disease).</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head></head><label></label><figDesc><div><p><s>Erythematous-violaceous cutaneous lesions with secondary changes of atrophic scarring, dyspigmentation, often follicular hyperkeratosis/plugging (scalp) leading to scarring alopecia on the scalp.Lesions have a preference for the head and neck, especially the conchal bowl, but may be found in nearly any location.If skin biopsy is performed, typical changes a must be present.characterizedby(1)change in consciousness or level of arousal with reduced ability to focus, and (2) symptom development over hours to &lt;2 days, and (3) symptom fluctuation throughout the day, and (4) either (4a) acute/subacute change in cognition (e.g.</s><s>memory deficit or disorientation), or (4b) change in behavior, mood, or affect (e.g.</s><s>restlessness, reversal of sleep/wake cycle, etc.)</s></p></div></figDesc><table><row><cell>Nominal Group Technique (2015)</cell><cell cols="3">Literature Review and Iterative Revisions (through October 2016)</cell></row><row><cell>neuritis, stroke or acute confusional state)</cell><cell cols="3">• Delirium: • Psychosis: characterized by (1) delusions and/or hallucinations without insight and (2)</cell></row><row><cell></cell><cell></cell><cell cols="2">absence of delirium</cell></row><row><cell></cell><cell>•</cell><cell cols="2">Seizure: primary generalized seizures or partial/focal seizures, with independent</cell></row><row><cell></cell><cell></cell><cell cols="2">description by a reliable witness. If EEG is performed, abnormalities must be present</cell></row><row><cell></cell><cell>•</cell><cell cols="2">Mononeuropathy (single or multiplex) or cranial neuropathy:</cell></row><row><cell></cell><cell></cell><cell>-</cell><cell>Mononeuropathy: either motor or sensory disturbance in distribution of</cell></row><row><cell></cell><cell></cell><cell></cell><cell>one or more peripheral nerves on physical examination, or abnormalities on</cell></row><row><cell></cell><cell></cell><cell></cell><cell>nerve conduction study or EMG</cell></row><row><cell></cell><cell></cell><cell>-</cell><cell>Cranial neuropathy: disorder of sensory and/or motor function of one or</cell></row><row><cell></cell><cell></cell><cell></cell><cell>more cranial nerves, including optic neuritis</cell></row><row><cell></cell><cell cols="3">[Eliminated chorea, myelitis, stroke; added mononeuropathy; broadened optic neuritis to cranial</cell></row><row><cell></cell><cell cols="3">neuropathy; term "acute confusional state" changed to "delirium" per ACR 1999 nomenclature 27 ]</cell></row><row><cell>Serositis (pleural or pericardial</cell><cell cols="2">Serositis domain:</cell></row><row><cell>effusion) pleurisy, pericarditis, abdominal serositis</cell><cell>•</cell><cell cols="2">Pleural or pericardial effusion: imaging evidence (such as ultrasound, x-ray, CT scan, MRI) of pleural or pericardial effusion, or both, not meeting the definition of</cell></row><row><cell></cell><cell></cell><cell cols="2">acute pericarditis below</cell></row><row><cell></cell><cell>•</cell><cell cols="2">Acute pericarditis: ≥2 of: (1) pericardial chest pain (sharp, worse with inspiration,</cell></row><row><cell></cell><cell></cell><cell cols="2">improved by leaning forward), (2) pericardial rub, (3) EKG with new widespread ST-</cell></row><row><cell></cell><cell></cell><cell cols="2">elevation or PR depression, (4) new or worsened pericardial effusion on imaging (such</cell></row><row><cell></cell><cell></cell><cell cols="2">as ultrasound, x-ray, CT scan, MRI)</cell></row><row><cell></cell><cell cols="3">[Eliminated pleurisy, abdominal serositis]</cell></row><row><cell>Leukopenia (&lt;4000/mm3 on 2 or more</cell><cell cols="3">3 Celsius with no other source identified Hematologic domain:</cell></row><row><cell>occasions)</cell><cell>•</cell><cell cols="2">Leukopenia: WBC &lt;4,000/mm 3</cell></row><row><cell>Rash with dermoepidermal interface Thrombocytopenia &lt; 100,000 on 2 or more occasions changes and immunoglobulin and/or complement deposition on immunofluorescence Alopecia with associated scalp Autoimmune hemolytic anemia</cell><cell cols="3">Cutaneous domain: • Thrombocytopenia: Platelets &lt;100,000/mm 3 • Oral ulcers, not necessarily observed by a physician [eliminated "on the hard palate"] • Autoimmune hemolysis with (1) evidence of hemolysis, such as reticulocytosis, low • Non-scarring alopecia, not necessarily observed by a physician [eliminated "scalp inflammation"] haptoglobin, elevated indirect bilirubin, elevated LDH and (2) positive Coomb's (direct antiglobulin test)</cell></row><row><cell>inflammation Oral mucosal lesions on the hard palate</cell><cell cols="3">• [Only need to occur once] Subacute cutaneous lupus: Annular or papulosquamous (psoriasiform) cutaneous eruption, usually photodistributed. If skin biopsy is performed, typical changes a must</cell></row><row><cell>Acute cutaneous lupus: SLICC Lupus nephritis by renal biopsy with definition immune deposits Chronic cutaneous: SLICC definition Persistent proteinuria (&gt;0.5g/day)</cell><cell cols="3">be present. Renal domain: • Proteinuria&gt;0.5g/24h: on 24 hour urine collection or spot urine protein-to-creatinine ratio representing &gt;0.5g protein/24h</cell></row><row><cell>Active urine sediment (without UTI)</cell><cell>•</cell><cell cols="2">Renal biopsy: International Society of Nephrology/Renal Pathology Society (ISN/</cell></row><row><cell></cell><cell></cell><cell cols="2">RPS) 2003 classification findings b</cell></row><row><cell></cell><cell></cell><cell>-</cell><cell>Class II or V lupus nephritis</cell></row><row><cell></cell><cell></cell><cell>-</cell><cell>Class III, IV, or VI lupus nephritis</cell></row><row><cell>Arthritis: inflammatory arthritis with</cell><cell cols="3">Arthritis domain: [Eliminated active urine sediment]</cell></row><row><cell>tenderness or swelling</cell><cell cols="3">• Immunologic Domains and Criteria Synovitis in ≥2 joints: characterized by joint swelling and tenderness. If x-rays are obtained and erosions are present, or if anti-CCP assay is obtained and is ≥3× upper</cell></row><row><cell></cell><cell></cell><cell cols="2">limit of normal, then do not score this item.</cell></row><row><cell>Antiphospholipid antibodies (LA,</cell><cell cols="3">Antiphospholipid antibodies domain:</cell></row><row><cell>anticardiolipin, anti-B2GPI, or prolonged RVVT)</cell><cell>•</cell><cell cols="2">AnticardiolipinIgG (&gt;40 GPL units) or anti-β2GP1 IgG (&gt;40 units) or lupus anticoagulant positive</cell></row><row><cell cols="4">Arthritis Care Res (Hoboken). Author manuscript; available in PMC 2018 June 12.</cell></row></table><note><p><s>•Acute cutaneous lupus: Malar rash (localized) or maculopapular rash (generalized), with or without photosensitivity.</s><s>If skin biopsy is performed, typical changes a must be present • Discoid lupus:</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 2</head><label>2</label><figDesc><div><p><s>Patient populations in studies reporting sensitivity and specificity of candidate SLE classification criteria</s></p></div></figDesc><table><row><cell>Study</cell><cell cols="2">Patient populations</cell><cell></cell></row><row><cell></cell><cell cols="3">SLE (n) Non-SLE (n) Medical conditions (n) in non-SLE group</cell></row><row><cell>ARA 1971 preliminary</cell><cell>245</cell><cell>451</cell><cell>RA (234), non-rheumatic diseases (217)</cell></row><row><cell>SLE classification</cell><cell></cell><cell></cell><cell></cell></row><row><cell>criteria 15</cell><cell></cell><cell></cell><cell></cell></row><row><cell>ACR 1982 revised criteria</cell><cell>177</cell><cell>162</cell><cell>RA (95), scleroderma (16), juvenile onset arthritis (7), dermatomyositis (6); &lt;5 of</cell></row><row><cell>for the classification of</cell><cell></cell><cell></cell><cell>each of the following: ankylosing spondylitis, psoriatic arthritis, Reiter's syndrome,</cell></row><row><cell>SLE 16*</cell><cell></cell><cell></cell><cell>osteoarthritis, mixed connective tissue disease, diagnosis not specified, Sjögren'ssyndrome, polyarthritis, Behcet's syndrome, hyperlipidemia, reflex</cell></row><row><cell></cell><cell></cell><cell></cell><cell>sympathetic dystrophy, Wegener's granulomatosus, vasculitis, regional enteritis,</cell></row><row><cell></cell><cell></cell><cell></cell><cell>discoid lupus, undifferentiated connective tissue disease, chronic active hepatitis,</cell></row><row><cell></cell><cell></cell><cell></cell><cell>multicentric reticulohistiocytosis</cell></row><row><cell>SLICC 2012 criteria for classification of SLE 18</cell><cell>310 +</cell><cell>392 +</cell><cell>RA (119), myositis (55), chronic cutaneous lupus (50), undifferentiated connective tissue disease (44), vasculitis (37), primary antiphospholipid syndrome (33),</cell></row><row><cell></cell><cell></cell><cell></cell><cell>scleroderma (28), fibromyalgia (25), Sjögren'ssyndrome (15), rosacea (8), psoriasis</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(7), sarcoidosis (1), juvenile idiopathic arthritis (1)</cell></row><row><cell>Early SLE cohort study 19</cell><cell>389</cell><cell>227</cell><cell>Undifferentiated connective tissue disease (136), Sjögren's syndrome (22), RA (13),</cell></row><row><cell></cell><cell></cell><cell></cell><cell>scleroderma (10), fibromyalgia (10), primary Raynaud's (10), mixed connective</cell></row><row><cell></cell><cell></cell><cell></cell><cell>tissue disease (9), thyroiditis (8), hematologic disease (5), infection (4), autoimmune</cell></row><row><cell></cell><cell></cell><cell></cell><cell>hepatitis (1), other (20)</cell></row><row><cell>Study of low complements in new-</cell><cell>158 #</cell><cell>2,294</cell><cell>"Other" diseases including malignancy, infection, cardiovascular disease, neuropathy (1,048), non-SLE rheumatic disease including connective tissue disease, primary</cell></row><row><cell>onset SLE 20</cell><cell></cell><cell></cell><cell>vasculitis, spondyloarthritis, metabolic joint disease (622), hematologic disease</cell></row><row><cell></cell><cell></cell><cell></cell><cell>including leukemia, myelodysplastic syndromes, lymphoma, chronic</cell></row><row><cell></cell><cell></cell><cell></cell><cell>myeloproliferative disorders, non-autoimmune anemia, thrombocytopenia, leukopenia</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(366), nephropathy including proteinuria, hematuria, renal insufficiency (258)</cell></row></table><note><p><s>Abbreviations: ARA, American Rheumatism Association.ACR, American College of Rheumatology.SLICC, Systemic Lupus International Collaborating Clinics.</s><s>RA, rheumatoid arthritis.</s><s>* The 1997 update did not publish sensitivity/specificity data + Among 716 cases contributed by the investigators, consensus on SLE present vs. absent was reached on 702; among these, SLE was considered present in 310.</s><s>The distribution of non-SLE diseases presented in this table reflects what was reported among the initial 716 cases.</s><s># New-onset SLE with biopsy-proven lupus nephritis with positive ANA or positive anti-dsDNA, or fulfilling ≥4 of 16 SLICC SLE classification criteria excluding low complement Arthritis Care Res (Hoboken).</s><s>Author manuscript; available in PMC 2018 June 12.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 3</head><label>3</label><figDesc><div><p><s>Sensitivity and specificity of candidate SLE classification criteria from a literature review *</s></p></div></figDesc><table><row><cell>Candidate criteria</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>including seizures, psychosis, chorea, myelitis, optic neuritis, stroke, or acute confusional state</head><label></label><figDesc></figDesc><table><row><cell></cell><cell>seizure: 100,</cell><cell>psychosis 99,</cell><cell>stroke 100</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Specificity (%) *</cell><cell cols="2">99 o</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">97 t</cell><cell>95 v</cell><cell>98.0 x</cell><cell>99.5 z</cell></row><row><cell></cell><cell cols="2">99 m , 99 n</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">89 r , 96 s</cell><cell>89 u</cell><cell>99 w</cell><cell>99 y</cell></row><row><cell>Sensitivity (%) *</cell><cell cols="2">5.5 o Early SLE cohort 19 : seizure 2.8, psychosis 1, stroke 1</cell><cell>Early SLE cohort 25 chorea 0.4,</cell><cell>myelopathy 0.8, cranial neuropathy</cell><cell>0.9 p (optic neuritis not reported</cell><cell>separately) and 1.8 38,q , acute</cell><cell>confusional state 1.4,</cell><cell>mononeuropathy (not a candidate</cell><cell>criterion) 1.5</cell><cell cols="2">35 t</cell><cell>46 v</cell><cell>13.5 x</cell><cell>7 z</cell></row><row><cell></cell><cell cols="2">12 m , 13 n</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">52 r ,18 s</cell><cell>46 u</cell><cell>21 w</cell><cell>18 y</cell></row><row><cell>Candidate criteria</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Serositis, including pleural or pericardial effusion, pleurisy,</cell><cell>pericarditis, and abdominal serositis</cell><cell>Leukopenia (&lt;4000/mm3 on ≥2 occasions)</cell><cell>Thrombocytopenia (&lt;100,000/mm3 on ≥2 occasions)</cell><cell>Autoimmune hemolytic anemia</cell></row></table><note><p><s>Arthritis Care Res (Hoboken).</s><s>Author manuscript; available in PMC 2018 June 12.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>ACR 1982 16 SLICC 2012 18 Other ACR 1982 16 SLICC 2012 18 Other Lupus nephritis by renal biopsy with immune deposits</head><label></label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>90 ll , , 88.5 mm</cell><cell>69 nn , 90 oo</cell><cell></cell></row><row><cell>Not reported</cell><cell>96 cc</cell><cell>96 ee</cell><cell cols="2">86 gg</cell><cell>93 kk</cell><cell>96 qq</cell><cell>98.7 ss</cell></row><row><cell>100 aa</cell><cell>94 bb</cell><cell>97 dd</cell><cell cols="2">Not reported ff</cell><cell>91 hh , 65 ii , 70 jj</cell><cell>92 pp</cell><cell>95 rr</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Newly diagnosed SLE 20 , : 6 ll</cell><cell>11 mm , 73 oo , 90.5 nn</cell><cell></cell><cell>Early SLE cohort 19</cell></row><row><cell>Not reported</cell><cell>33 cc</cell><cell>33 ee</cell><cell cols="2">54 gg</cell><cell>59 kk</cell><cell>57 qq</cell><cell>26 ss</cell><cell>Not reported</cell></row><row><cell>83 aa</cell><cell>50 bb</cell><cell>36 dd</cell><cell cols="2">Not reported ff</cell><cell>64 hh , 64 ii , 70 jj</cell><cell>67 pp</cell><cell>31 rr</cell><cell>Not reported</cell></row><row><cell></cell><cell>Persistent proteinuria (&gt;0.5 g/day)</cell><cell>Active urine sediment (without urinary tract infection)</cell><cell>Antiphospholipid antibodies (lupus anticoagulant,</cell><cell>anticardiolipin, anti-B2GP1, or prolonged RVVT)</cell><cell>Complement protein</cell><cell>Anti-dsDNA antibody</cell><cell>Anti-Smith antibody</cell><cell>Presence of multiple autoantibodies</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Arthritis Care Res (Hoboken). Author manuscript; available in PMC 2018 June 12.</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>Funding: This work was jointly supported by the European League Against Rheumatism and the American College of Rheumatology.</s><s>Dr. Tedeschi's work on this project was supported in part by the Lupus Foundation of America Career Development Award and NIH-NIAMS L30 AR070514.</s><s>Dr. Johnson was supported by a Canadian Institutes of Health Research New Investigator Award.</s></p><p><s>The authors would like to thank the following individuals for their support of this project: Amy Miller for her outstanding organizational support and Zahi Touma, MD.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary Material</head><p><s>Refer to Web version on PubMed Central for supplementary material.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Significance and Innovations</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>•</head><p><s>We conducted a literature review to understand the performance characteristics of candidate classification criteria for SLE.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>•</head><p><s>Organization of criteria into independent additive domains will facilitate, in the next phase of this international EULAR/ACR joint project, the development of an additive scoring system, with identification of a threshold score above which a patient will be classified as SLE for the purpose of clinical research studies.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author Manuscript</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Toward new criteria for systemic lupus erythematosus -a standpoint</title>
		<author>
			<persName><forename type="first">M</forename><surname>Aringer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Dorner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Leuchten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Johnson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lupus</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="805" to="811" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 27252256</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Methodological and statistical approaches to criteria development in rheumatic diseases</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Felson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Anderson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Baillieres Clin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="253" to="266" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note>PubMed: 7656339</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Development of classification and response criteria for rheumatic diseases</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Solomon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dougados</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Felson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Hawker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Katz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="348" to="352" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note>PubMed: 16739201</note>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title level="m" type="main">Classification criteria for rheumatic diseases: why and how? Arthritis Rheum</title>
		<author>
			<persName><forename type="first">M</forename><surname>Dougados</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gossec</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2007">2007</date>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="1112" to="1115" />
		</imprint>
	</monogr>
	<note>PubMed: 17907226</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Classification criteria in rheumatic diseases: a review of methodologic properties</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">N</forename><surname>Goek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Singh-Grewal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Vlad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Feldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Felson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="1119" to="1133" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17907227</note>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">Identification of candidate items for revised classification criteria for systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">G</forename><surname>Schmajuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Hoyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Aringer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Dorner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">I</forename><surname>Daikh</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>abstract</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="issue">10</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title level="m" type="main">Multi-center Delphi exercise reveals important key items in classifying SLE</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Hoyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schmajuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Aringer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">I</forename><surname>Daikh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Dorner</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>abstract</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="issue">10</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title level="m" type="main">Use of Nominal Group Technique to determine candidate items for SLE classification criteria development</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Khanna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cervera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Costedoat-Chalumeau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Gladman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Hahn</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>abstract</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="issue">10</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Performance of antinuclear antibodies for classifying systemic lupus erythematosus: a systematic literature review and meta-regression of diagnostic data</title>
		<author>
			<persName><forename type="first">N</forename><surname>Leuchten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schoels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Smolen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Aringer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">I</forename><surname>Daikh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res</title>
		<imprint>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>in press</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Validation of potential classification criteria for systemic sclerosis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fransen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Khanna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Van Den Hoogen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Medsger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="358" to="367" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Naden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fransen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Van Den Hoogen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Pope</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baron</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Epi</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="706" to="714" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative</title>
		<author>
			<persName><forename type="first">F</forename><surname>Van Den Hoogen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Khanna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fransen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tyndall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="2737" to="2747" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>PubMed: 24122180</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report</title>
		<author>
			<persName><forename type="first">T</forename><surname>Neogi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Aletaha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Silman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Naden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Felson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Aggarwal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="2582" to="2591" />
			<date type="published" when="2010">2010. 2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20872596</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative</title>
		<author>
			<persName><forename type="first">T</forename><surname>Neogi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Jansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Dalbeth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fransen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Schumacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Berendsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="2557" to="2568" />
			<date type="published" when="2015">2015. 2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Preliminary criteria for the classification of systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Reynolds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Franklin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Kulka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Ropes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Shulman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bulletin Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="643" to="648" />
			<date type="published" when="1971">1971</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">The 1982 revised criteria for the classification of systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Fries</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Masi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Mcshane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">F</forename><surname>Rothfield</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1271" to="1277" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
	<note>PubMed: 7138600</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Hochberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page">1725</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">M</forename><surname>Petri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Orbai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Alarcon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Merrill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Fortin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="2677" to="2686" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>PubMed: 22553077</note>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<title level="m" type="main">Do patients with SLE at onset differ from mimickers? A comparison of clinical and serological manifestations in a multicenter cohort to inform the development of new classification criteria for SLE</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Touma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Costenbader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Hoyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Navara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bonfa</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">558</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Diagnostic value of serum complement C3 and C4 levels in Chinese patients with systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zheng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinl Rheum</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="471" to="477" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Fever of unknown origin: an old friend revisited</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Petersdorf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Int Med</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="21" to="22" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
	<note>PubMed: 1728921</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Morbidity and mortality in systemic lupus erythematosus during a 5-year period</title>
		<author>
			<persName><forename type="first">R</forename><surname>Cervera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Khamashta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Font</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Sebastiani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lavilla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medicine (Baltimore)</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="167" to="175" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note>PubMed: 10352648</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Distinctive cutaneous subsets in the spectrum of lupus erythematosus</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Gilliam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Sontheimer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="471" to="475" />
			<date type="published" when="1981">1981</date>
		</imprint>
	</monogr>
	<note>PubMed: 7229150</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Items for developing classification criteria in discoid lupus erythematosus: results of a consensus exercise</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Elman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Joyce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Nyberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Furukawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Goodfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hasegawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Derm</title>
		<imprint>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Hanly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Urowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Bae</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Wallace</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="529" to="535" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 19359262</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Cluster analysis of an array of autoantibodies in neuropsychiatric systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Zirkzee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Magro</forename><surname>Checa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sohrabian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Steup-Beekman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheum</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="1720" to="1721" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed: 25086139</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes</title>
	</analytic>
	<monogr>
		<title level="m">ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature</title>
				<imprint>
			<date type="published" when="1999">1999</date>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="599" to="608" />
		</imprint>
	</monogr>
	<note>PubMed: 10211873</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Adler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Charron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Imazio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Badano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Baron-Esquivias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bogaert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cardiology</title>
		<imprint>
			<date type="published" when="2015">2015</date>
			<publisher>ESC</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="2921" to="2964" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 26320112</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">The classification of glomerulonephritis in systemic lupus erythematosus revisited</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Weening</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>'agati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">D</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Seshan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">V</forename><surname>Alpers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Appel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="521" to="530" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 14717922</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials</title>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="421" to="432" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note>PubMed: 16453282</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort</title>
		<author>
			<persName><forename type="first">M</forename><surname>Dall'era</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Cisternas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Smilek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Straub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Houssiau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cervera</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="1305" to="1313" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<monogr>
		<title level="m" type="main">International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome</title>
		<author>
			<persName><forename type="first">S</forename><surname>Miyakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lockshin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Atsumi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Branch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Brey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cervera</surname></persName>
		</author>
		<imprint>
			<publisher>APS</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">J Thromb Haemostasis</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="295" to="306" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note>PubMed: 16420554</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Hanly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Urowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sanchez-Guerrero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Bae</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Wallace</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="265" to="273" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17195230</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Clinical and serological features distinguish patients with incomplete lupus classification from systemic lupus erythematosus patients and controls</title>
		<author>
			<persName><forename type="first">T</forename><surname>Aberle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Bourn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Munroe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Guthridge</surname></persName>
		</author>
		<idno>doi: 10.1002/ acr.23201</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res</title>
		<imprint>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>epub ahead of print</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Discerning risk of disease transition in relatives of systemic lupus erythematosus patients utilizing soluble mediators and clinical features</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Munroe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Kamen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Guthridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">B</forename><surname>Niewold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Costenbader</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="630" to="642" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies</title>
		<author>
			<persName><forename type="first">R</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Munroe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Guthridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Bean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Fife</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Autoimmun</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="182" to="193" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 27338520</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-doublestranded DNA and standard complement measurements</title>
		<author>
			<persName><forename type="first">C</forename><surname>Putterman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Furie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ramsey-Goldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Askanase</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Buyon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kalunian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lupus Sci Med</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page">e000056</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed: 25396070</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Hanly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mccurdy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fougere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Douglas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Thompson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheum</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="2156" to="2162" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>PubMed: 15517627</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
